 |
||
|
Razan General Trading & Contracting Co |
|
|
|||||||||||
|
|||||||||||
|
American Professor E. Michael Molnar, M.D. graduated summa cum laude, 4.0. grade average, from the Faculty of Medicine, Komensky University, Bratislava, Czechoslovakia. Following the invasion of Warsaw Pact armies into Czechoslovakia on August 21, 1968, he immigrated to the United States at the age of 26, already certified by the Czechoslovak Board of Head and Neck Surgery, and appointed a County Consultant for Pediatric Head & Neck Surgery. Professor Professor Dr. Molnar repeated his residency training (1971-75) as required by US authorities. During this period he was an Assistant at A. Lincoln School of Medicine in Chicago, Ill., and a graduate student at the University of Illinois Medical Center, Chicago, Ill. In 1975 he was certified by the American Board of Head and Neck Surgery and received a Master of Science degree in physiology from the University of Illinois at the Medical Center in Chicago, Ill. After 1975, Professor Dr. Molnar developed a private practice of head & neck, and plastic & reconstructive surgery in Los Angeles, with staff privileges at 15 major hospitals. He consulted at 8 private multiple specialty clinics, and taught as a Clinical Professor at C. Drew Medical School in Los Angeles, Calif. While his practice had become the largest in Southern California, news of the horrible death of his father from complications of diabetes mellitus in 1976 caused Professor Dr. Molnar to search for new treatments for incurable or no longer treatable diseases. This research culminated in a public educational campaign about such therapies through his own live radio and television programs. He also did extensive lecturing, and published in 1984 in the U.S., the first book for the general public about aging disease written by a licensed U.S. physician. Unexpectedly, for a physician from Europe, such activities brought on severe attacks by the U.S. medical industry and Professor Dr. Molnar decided to return to Europe in 1988 to pursue his research. He began to concentrate on stem cell transplantation as the most promising therapy of all. In 1988, he secured the approval of the Yugoslav authorities to organize a clinical research project on cell transplantation. The project had to be stopped in 1990 due to the civil war. Professor Dr. Molnar immediately approached Prof. Professor Dr. Chazov, U.S.S.R. Minister of Health, with a request to continue the project in the Soviet Union. Professor Dr. Molnar was invited by the U.S.S.R. Ministry of Health to Moscow in June 1990 to launch a very successful project on the use of cell transplantation as a treatment for a wide variety of incurable and no longer treatable diseases. This effort was accomplished in cooperation with the 20 top Russian medical research institutes. Professor Dr. Molnar linked the classical German and Soviet schools of cell transplantation. He is one of the few physicians with extensive experience in both animal and human fetal cell transplantation, and qualified to warn against the dangers of human embryonic stem cell transplantation. Professor Dr. Molnar explains in his textbook on stem cell transplantation in English his preference for stem cell xeno-transplantation (animal) over allo-transplantation. Xeno-transplantation is safer, available for unlimited number of patients, less expensive, and more therapeutically effective than allo-transplantation, if cell xeno-transplants are prepared by the method described in his new book. Directly, or under Professor Dr. Molnar’s supervision, 5,000 patients have been treated by various techniques of stem cell transplantation in the , Switzerland, U.S.S.R./Russia, U.S.A., Germany, Italy, Czechoslovakia, Mexico, Malaysia, Singapore, Thailand, Pakistan, Qatar, South Africa, and Nigeria. His research and stem cell treatments have been reported by the media including: CBS 60 Minutes, Stern Magazine, Spiegel T.V. with pan-European broadcasting in major cities in the ‘90s. In September 1996, the U.S. FDA issued a draft of guidelines on the use of cell & tissue xeno-transplantation, a Pyrrhic victory for Professor Dr. Molnar, which resulted in official cooperation with U.S. FDA (Dec.’96). In 1998, he set up the manufacturing of stem cell xeno-transplants, based on his U.S. patent application “Cell and Tissue Xenotransplants” and related know-how. In February 1999, four IND applications, written by Professor Dr. Molnar, were filed with U.S. FDA for treatment of diabetic retinopathy, diabetic nephropathy, diabetic neuropathy and diabetic vasculopathy, by cell transplantation of animal fetal origin. Professor Dr. Molnar has lectured on stem cell transplantation in 25 countries. He has published two books, contributed chapters for other books, and published 30 articles in peer-reviewed journals. He is the author of four IND applications to U.S. FDA, which helped establish GMP guidelines for stem cell transplantation. He has written therapeutic protocols for stem cell transplantation treatment for all pertinent diseases, and has five extensive web sites about stem cell transplantation. Professor Dr. Molnar is very likely the worlds’ foremost expert on stem cell transplantation. He has created during the last 25 years ideas, concepts, visions, clinical research project designs, in this field. He has written medical and scientific reports, lectured, educated medical profession and public. He is the most experienced clinical practitioner of stem cell transplantation. With the help of his team he developed the manufacturing of stem cell xeno-transplants using his expertise on rules of medical regulatory agencies and GMP. He has been a relentless ambassador for stem cell transplantation. This experience has allowed him to write an extensive first textbook book on stem cell transplantation in English. Professor Dr. Molnar is the CEO/ Managing Director (since 1989) of Bio Cellular R & D Organization LLC, the first and only manufacturer of live stem cell xeno-transplants in the world with production starting in 1998. Study of his book teaches the medical professional all that is necessary to know for an effective clinical practice in stem cell transplantation. |
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
